Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
Part of paid clinical trials in Beverly Hills, California.
- Sponsor
- Takeda
- Study ID
- NCT00672620
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Vortioxetine — DRUGEncapsulated vortioxetine immediate-release tablets
- Duloxetine — DRUGDuloxetine capsules
- Placebo — DRUGPlacebo-matching capsules
Study Details
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
Key Dates
- Start date
- Apr 30, 2008
- Status verified
- Oct 2013
- Primary completion
- Nov 30, 2008
- Completion
- Dec 31, 2008
Study Design
- Enrollment
- 611 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Vortioxetine 2.5 mgVortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
- Experimental: Vortioxetine 5 mgVortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
- Active Comparator: Duloxetine 60 mgDuloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.
- Placebo Comparator: PlaceboPlacebo-matching capsules, orally, once daily for up to 9 weeks.
Primary Outcome Measure
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8 [ Time Frame: Baseline and Week 8 ]
Locations (38)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Beverly Hills | California | - | - |
| - | Irvine | California | - | - |
| - | Santa Ana | California | - | - |
| - | Torrance | California | - | - |
| - | Upland | California | - | - |
| - | Bradenton | Florida | - | - |
| - | Coral Springs | Florida | - | - |
| - | Fort Walton Beach | Florida | - | - |
| - | Gainesville | Florida | - | - |
| - | Jacksonville | Florida | - | - |
| - | Maitland | Florida | - | - |
| - | Orlando | Florida | - | - |
| - | South Miami | Florida | - | - |
| - | West Palm Beach | Florida | - | - |
| - | Atlanta | Georgia | - | - |
| - | Smyrna | Georgia | - | - |
| - | Chicago | Illinois | - | - |
| - | Libertyville | Illinois | - | - |
| - | Oak Brook | Illinois | - | - |
| - | Prairie Village | Kansas | - | - |
| - | Owensboro | Kentucky | - | - |
| - | Baltimore | Maryland | - | - |
| - | Pittsfield | Massachusetts | - | - |
| - | Worcester | Massachusetts | - | - |
| - | Flowood | Mississippi | - | - |
| - | New York | New York | - | - |
| - | Olean | New York | - | - |
| - | Beachwood | Ohio | - | - |
| - | Toledo | Ohio | - | - |
| - | Oklahoma City | Oklahoma | - | - |
| - | Allenport | Pennsylvania | - | - |
| - | Lancaster | Pennsylvania | - | - |
| - | Memphis | Tennessee | - | - |
| - | Austin | Texas | - | - |
| - | San Antonio | Texas | - | - |
| - | Salt Lake City | Utah | - | - |
| - | Seattle | Washington | - | - |
| - | Milwaukee | Wisconsin | - | - |
Find similar trials in Beverly Hills, CA
By condition
By specialty
Related Studies
- Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersPHASE2 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderPHASE1 · Recruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- DBS for DepressionRecruiting · Baylor College of Medicine · Dallas, Texas
- Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar DisorderEARLY_PHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts